<h4>Background</h4>Cluster of differentiation 38 (CD38) monoclonal antibodies, including daratumumab and isatuximab, have demonstrated clinical activity in relapsed or refractory multiple myeloma (MM). Here, CD38 is linked to plasma cell myeloma.